GTH - Genetron up 2% after HCCscreen selected by NCC Wuxi for public health initiative in China

Genetron ([[GTH]] +1.5%) says HCCscreen selected by the National Cancer Center and the Wuxi municipal government for use in the “Liver Cancer Early Screening Comprehensive Prevention and Control Project”, a public health initiative in China.The goal of the Project is to increase the awareness of liver cancer early screening, and to become a pilot city model in China. Under the project, Wuxi has selected HCCscreen for local residents who are high-risk individuals for HCC,  and is committed to administering 150K tests over a period of three years.HCCscreen is intended for early detection of hepatocellular carcinoma in individuals who are designated to be at high-risk due to chronic HBV infection and/or liver cirrhosis.Separately, Genetron Health has formed a new operating center through a joint venture agreement with Wuxi, in which the parties will closely collaborate on advancing the liver cancer early screening market in China, through the adoption of HCCscreen. Under this joint venture agreement, both parties will contribute capital, and

For further details see:

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China